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cancer mortality demonstrates the need for
screening: a population based study in Ireland,
1994-2010
Nicholas Clarke1,2*†, Joseph McDevitt1†, Patricia M Kearney2† and Linda Sharp1†Abstract
Background: This paper describes trends in colorectal cancer incidence, survival and mortality from 1994 to 2010
in Ireland prior to the introduction of population-based screening.
Methods: We examined incidence (National Cancer Registry Ireland (NCRI) and mortality (Central Statistics Office)
from 1994 to 2010. Age standardised rates (ASR) for incidence and mortality have been calculated, weighted by the
European standard population. Annual percentage change was calculated in addition to testing for linear trends in
treatment and case fraction of early and late stage disease. Relative survival was calculated considering deaths from
all causes.
Results: The colorectal cancer ASR was 63.7 per 100,000 in males and 38.7 per 100,000 in females in 2010. There
was little change in the ASR over time in either sex, or when colon and rectal cancers were considered separately;
however the number of incident cancers increased significantly during 1994-2010 (1752 to 2298). The case fractions
of late stage (III/IV) colon and rectal cancers rose significantly over time. One and 5 year relative survival improved
for both sexes between the periods 1994-2008. Colorectal cancer mortality ASRs decreased annually from 1994-2009 by
1.8% (95% CI -2.2, -1.4). Rectal cancer mortality ASRs rose annually by 2.4% (95% CI 1.1, 3.6) and 2.8% (95% CI 1.2, 4.4) in
males and females respectively.
Conclusions: Increases in late-stage disease and rectal cancer mortality demonstrate an urgent need for colorectal
cancer screening. However, the narrow age range at which screening is initially being rolled-out in Ireland means
that the full potential for reductions in late-stage cancers and incidence and mortality are unlikely to be achieved.
While it is possible that the observed increase in rectal cancer mortality may be partly an artefact of cause of death
misclassification, it could also be explained by variations in treatment and adherence to best practice guidelines;
further investigation is warranted.
Keywords: Colorectal, Cancer, Ireland, Incidence, Survival, Mortality, Mass screening, Colon, Rectal* Correspondence: n.clarke@ncri.ie
†Equal contributors
1National Cancer Registry, Building 6800, Cork Airport Business Park, Kinsale
Road, Cork, Ireland
2Department of Epidemiology and Public Health, Fourth Floor, Western
Gateway Building, University College Cork, Cork, Ireland
© 2014 Clarke et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Clarke et al. BMC Gastroenterology 2014, 14:92 Page 2 of 10
http://www.biomedcentral.com/1471-230X/14/92Background
Over 1.23 million colorectal cancers are diagnosed world-
wide annually [1] with 609 000 deaths [1]. Colorectal
cancer is highly preventable if diagnosed early and
treated. Screening has been available for many years
through several modalities, including colonoscopy, sig-
moidoscopy, and faecal-based tests [2-4]. Faecal-based
tests, notably faecal occult blood testing (FOBT), are
generally the route through which colorectal cancer
screening programmes are being delivered internation-
ally [5,6]. More recently faecal immunochemical test-
ing (FIT) has been recommended for screening due to
its improved sensitivity and specificity in detecting hu-
man haemoglobin and the fact that there is no need for
test recipients to undergo dietary restrictions (which
may be required for guaiac-based tests). Studies which
have used FIT suggest improved uptake compared to
other screening tests such as FOBT, possibly due to the
absence of dietary restrictions, the need for fewer samples,
absence of the need for storage if a one sample test, and
ease of use [7]. However the authors state that these re-
sults are inconclusive and require further investigation
from the patient’s perspective [7]. Recent European and
US guidelines recommend FIT as the initial screening test
in population-based screening programmes [8,9].
Screening aims to detect colorectal disease either at a
precancerous stage (when removal of polyps may prevent
cancers developing) or when cancers are at an early stage
(when treatment is more effective and patients may also
benefit from improved quality-of-life). Screening therefore
has the potential to reduce mortality, provided the service
is of high quality and coverage is high [8].
Although many European countries have established
screening programmes, until 2013, no programme was
in place in Ireland. In 2009, a health technology assess-
ment of population-based colorectal cancer screening
found that biennial FIT at ages 55-74 would be consid-
ered the optimal screening strategy in Ireland in terms
of potential for reducing incidence and mortality, and
cost-effectiveness [10]. The National Cancer Screening
Service launched BowelScreen, a national population-
based programme, in December 2012. This paper aims to
describe the population burden of colorectal cancer by exam-
ining trends in colorectal cancer incidence, mortality and
survival during 1994-2010, prior to nationwide screening.
Methods
We examined incidence for 1994-2010 and mortality for
1994-2009 (2009 was the latest year for which mortality
data was available at the time of the study). Information
on incident cases was abstracted from the National Cancer
Registry Ireland (NCRI). The NCRI records all cancers di-
agnosed in the population usually resident in Ireland
through active case finding by tumour registration officers.The completeness of registration for all invasive cancers
diagnosed to end 2008 was estimated to be over 97% [11].
The NCR has permission under the Health (Provision
of Information) Act 1997 to collect and hold data on all
persons diagnosed with cancer in Ireland. The use of
that data for research is covered by the Statutory Instru-
ment which established the Registry Board in 1991. All
datasets were anonymised prior to analysis.
Site of tumour was recorded according to the Inter-
national Classification of Diseases 10th revision (ICD10),
and analysis included all primary invasive cancers of the
colon (C18) and rectum (C19-C20) with a date of diag-
nosis during 01/01/1994 and 31/12/2010. For each diag-
nosed cancer, summary stage was derived from primary
tumour (T), regional nodes (N) and distant metastasis
(M) as recorded in pathology reports or, in the absence
of these, from clinical staging, according to TNM 5th
edition [12]. Where a patient was classified as MX (“distant
metastases cannot be assessed”), the M category was
defaulted to “M0” (no distant metastasis). For example,
a patient with stage composite T3N1MX was treated as
T3N1M0, stage III (Dukes C). Data on treatment re-
ceived during the first year post-diagnosis was defined
as planned first course of tumour directed treatment
administered within one year of the diagnosis date (-30
to 365 days) and aimed at removing, destroying or prevent-
ing further tumour growth and included four treatment
scenarios: (Surgery (Y/N), chemotherapy(Y/N), radio-
therapy(Y/N), or not treated [ICD9CM and ICD10-
AM]). Analyses of stage and treatment included cases
diagnosed during 1995-2009, as this information was in-
complete for 2010 cases and unreliable for 1994 cases,
the first year of national registration. Colorectal cancer
deaths (C18-20) were obtained from the Central Statis-
tics Office (CSO) [13].
Age-standardised rates (ASR) for incidence and mortal-
ity were weighted by the European standard population
using the direct method [14]. Trends presented as annual
percentage change (APC) in ASRs of incidence (1994-
2010) and mortality (1994-2009) were calculated using
Joinpoint regression [15]. Joinpoint regression was also
used to test for linear trends in treatment (1995-2009) and
case fraction of early (stage I/II) and late (stage III/IV) dis-
ease (1995-2009). For descriptive purposes, age category
percentages and treatment category percentages were
given for three diagnostic periods: 1995-1999, 2000-2004
and 2005-2009.
In the Irish cancer registry, follow-up of cases is pas-
sive, where registered cancer cases are linked to death
certificates provided by the CSO [16]. For survival ana-
lysis, the dataset was divided into three diagnostic pe-
riods: 1994-1998, 1999-2003 and 2004-2008. Survival
time was censored at 31 December 2009 to ensure all
cases had at least one year follow-up, and because this
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complete. Our manuscript was drafted in late 2013, a
point in time when we were confident that all deaths
certificates from the CSO were matched to the cancer
registry database. Cases which were preceded by another
cancer (other than non-melanoma skin cancer) were
excluded from survival analysis as were autopsy-only
cases, death certificate only cases (DCO), colorectal can-
cers concurrent with other invasive malignancy and colo-
rectal cancers diagnosed 2009-2010. Relative Survival
(RS), the ratio of observed survival among a group of cases
to the expected survival among the general population of
the same age, sex and country, was computed based on
deaths from all causes and using national life-tables [17].
Results
Incidence
The colorectal cancer ASR was 63.7 per 100,000 in males
and 38.7 per 100,000 in females in 2010. There was little
change in the ASR over time (Figure 1) in either sex, or
when colon and rectal cancers were considered separately.
However, the number of colorectal cancer cases in Ireland
increased from 1752 in 1994 to 2298 in 2010, an annual
rise of 2.1% (95% CI 1.8, 2.4; p < 0.001). The increase was
somewhat higher in males (983 in 1994; 1343 in 2010;Colorectal (C18-20) Colon (C18)
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Figure 1 Age standardised incidence rate and incident cases of coloreAPC= 2.3%, 95% CI 2.0, 2.7) than females (769 in 1994;
955 in 2010; APC = 1.8%, 95% CI 1.4, 2.1).
In males, 62% of cases were in the colon; this was 71%
in females. Increases in cases were observed in both colon
(APC males = 2.6%, 95% CI 2.0, 3.2; APC females = 1.8%,
95% CI 1.4, 2.3) and rectal cancer (APC males = 1.9%, 95%
CI 1.0, 2.4; APC females = 1.7%, 95% CI 1.4, 2.5).
Age distribution
Sixty nine percent of cases in males and 67% in females oc-
curred in those aged ≥65; similar proportions in each sex
were diagnosed aged 55-64 (males: 20%; females: 19%) and
<55 (males: 11%; females: 14%). Over the three periods
1995-1999, 2000-2004 and 2005-2009 there was no change
in the age distribution of either colon or rectal cancer in fe-
males or rectal cancer in males (data not shown).
Stage
During 1995-2009 early stage (I/II) colon cancers de-
creased by -1% annually in males (95% CI -1.8%, -0.1%)
and in females by -0.7% (95% CI -1.4%, -0.1%). Conversely
late stage (III/IV) colon cancers increased by 1.3% in
males (95% CI 0.6%, 2.1%) and by 1.6% in females (95% CI
0.9%, 2.3%). Similarly early stage rectal cancers decreased
by -2.1% (95% CI -2.8%, -1.4%) in males and -1.8% (95%Rectum (C19-20)
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ctal cancer by site of primary tumour and sex, 1994-2010.
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creased significantly (males: APC = 2.0%, 95% CI 1.2%,
2.7%; females: APC = 1.8%, 95% CI 0.7%, 2.8%; Figure 2).
Unstaged colon cancers decreased significantly in males
by -2.2% (95% CI -4.1%, -0.2%; p-trend <0.05) and by -3.3%
in females (95% CI -5.7%, -1.0%; p-trend < 0.05) annually.
There was no significant change in unstaged rectal cancers
in males (APC 0.6%, 95% CI -2.3%, 1.2%; p-trend = 0.5) or
females (APC= 0.2%, 95% CI-2.3%, 2.8; p-trend = 0.8).
Treatment
Use of cancer-directed surgery (i.e. resection) for colon can-
cer increased from 76% in 1995-1999 to 79% in 2005-2009
(APC 0.3%, 95% CI 0.0, 0.6; p = 0.027), while for rectal can-
cer there was little change, remaining at 74% over the same
period (APC -0.1%, 95% CI -0.5, 0.3; p = 0.54) (Figure 3).
Use of chemotherapy for colon cancer rose significant from
21% in 1995 to 40% in 2006, thereafter levelling off to 38%(A)
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Figure 2 Case fraction for stage of disease at presentation, by gende
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null hypothesis is that the APC = 0%: Alternative hypothesis is APC≠ 0%. Thup to 2009(APC= 5.7%, 95% CI 4.3, 7.1; p < 0.001). Simi-
larly, in rectal cancer, chemotherapy use increased signifi-
cantly from 22% in 1995 to 48% in 2002 (APC= 11.1%, 95%
CI 8.7, 13.5; p < 0.001), reaching 49% by 2009 (Figure 3).
Use of radiotherapy for rectal cancer increased significantly
from 18% in 1995 to 37% in 2001, thereafter levelling off to
just under 40% (APC 12.3%, 95% CI 9.1, 15.7; p < 0.001).
The proportion of rectal cancer patients who received pre-
surgery radiotherapy increased from 2% in 1995 to 13% in
2002 (APC 38.7%, 95% CI 28.7, 49.5; p < 0.001). Thereafter,
the proportion receiving this combination increased at a
slower rate from 18% in 2003 to 26% in 2009 (APC 9.9%,
95% CI 1.9, 18.4; p = 0.02) (Figure 3).
Survival
Relative survival improved over time for both sexes for
colon and rectal tumours. From 1994-1998 to 2004-2008
1-year colon cancer survival in males increased by 8(B)
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http://www.biomedcentral.com/1471-230X/14/92percentage points to 77% (95% CI 75%, 78%), and in fe-
males by 5 percentage points to 73% (95% CI 71%, 75%).
Five-year colon cancer survival increased by 8 percent-
age points to 58% (95% CI 56%, 61%) in males and by 7
percentage points to 59% (95% CI 56%, 62%) in females
over the same time (Figure 4). One-year rectal cancer
survival improved in males by 9 percentage points to
81% (95% CI 79%, 82%) and in females by 6 percentage
points to 80% (95% CI 78%, 83%); 5-year rectal cancer
survival in males improved by 9 percentage points to
55% (95% CI 52%, 59%) and in females by 9 percentage
points to 61% (95% CI 57%, 65%; Figure 5).
Mortality
In 2005-2009, on average 400 females (255 colon; 145
rectum) and 552 males (313 colon; 239 rectum) died
from colorectal cancer annually. Colon cancer deaths
declined over time in both sexes (males: 360 in 1994;
302 in 2009; APC = -1.7%, 95% CI -2.4%, -1.0%; females:
321 in 1994; 240 in 2009; APC = -2.1%, 95% CI -3.0%,
-1.2%). Rectal cancer deaths rose significantly in males
from 148 in 1994 to 262 in 2009 (APC = 4.6%, 95% CI
3.4%, 5.9%) and in females from 94 in 1994 to 141 in
2002 (APC = 4.4%, 95% CI 3.0%, 5.9%).
Colorectal cancer age-standardised mortality rates (ASR)
decreased by -1.8% (95% CI -2.2%, -1.4%) annually during
1994-2009. Colon cancer ASRs fell in both sexes (males:
APC= -3.7%, 95% CI 4.4%, -3.0%; females: APC= -4.2%,
95% CI -5.1%, -3.2%), but rectal cancer ASR (mortality) rose
(males: APC= 2.4%, 95% CI 1.1%, 3.6%; females: APC=
2.8%, 95% CI 1.2%, 4.4%; Figure 6).
Discussion
Over the past 20 years the number cases of colorectal
cancer has increased significantly in Ireland; however69 71
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population over time the rate has remained stable. Inter-
nationally colorectal cancer rates have stabilised in eco-
nomically developed countries and Ireland is no exception
in this regard [18]. In comparison to other European
countries, in 2008 Ireland had a higher incidence rate than
the EU average and 23% higher than the rate in the United
Kingdom [19]. In the European region incidence has in-
creased in males at a greater rate than female incidence
during the period 1988 to 2008 [20]. Survival was just
below the EU average but similar to the United Kingdom
[21]. The improvements in survival reported in this paper
were also seen in other European countries during the
1990s and early 2000s [21]. European 5 year survival of
colon cancer increased from 54.2% in the period 1999-
2001 to 58.1% in 2005-2007, and from 52.1% to 57.6% for
rectal cancer over the same period [22]. Although Irish
survival improved, it is still lower than the European aver-
age [22]. Our data indicates that survival continued to im-
prove for cases diagnosed during 2005-2009. While we did
not have detailed information on the dose and intensity of
chemotherapy and radiotherapy regimens, better uptake
in and application of treatment options during 1995-2009
correlate with the improvement in survival.
Stage
One of the striking findings of this study was that almost
half of cases had relatively late stage at diagnosis (stage
III/IV) and, over the period under investigation, the pro-
portion with stage III/IV disease increased from 42% to
50%. The increase in stage III/IV cancers is likely to be
as a result of more comprehensive investigation in the
peri-operative period, with improvements in imaging
and diagnostic methods, resulting in a significant shift
in stage allocation from stage I/II to stage III/IV over68 70
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number of nodes taken at resection increased over the
period 1995-2009, thereby leading to a situation where
the probability of finding a positive node(s) increased
commensurately, which would have tipped the balance
in favour of stage III/IV over stage I/II according to
UICC-TNM, 5th edition. However, we do not haveColorectal (C18-20) Colon (C18)
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Figure 6 Age standardised mortality rate and number of deaths for cdetails on node count to support this hypothesis. This
question will be addressed in a more comprehensive
study of stage migration in colorectal cancer at this
registry.
If effective, screening has the potential to change the
stage distribution of colorectal cancer in the population. As
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detected at significantly earlier stages in those invited to
participate in a screening programme using FIT [23]. In a
health technology assessment for Ireland, it was estimated
that, by year 10 of a programme, the percentage of cases
diagnosed at stages I/II would increase from 46% to
53% and stages III/IV decrease from 54% to 47% [10].
These estimates were based on screening targeted at
those aged 55-74 with a best case scenario uptake of
53% (based on the UK experience of FOBT screening)
[24]. Similar uptake has been achieved in pilot FIT
screening in Ireland [25]. The BowelScreen programme,
which has recently commenced, is initially inviting indi-
viduals aged 60-69. While the stated intention is to even-
tually include 55-74 year olds, this is likely to take a
number of years due to the development of colonoscopy
capacity. Therefore the estimates of potential reductions
in late stage disease are very unlikely to be achieved by
year 10 of the programme.
Mortality
In 2008 Ireland ranked midway of 30 European coun-
tries in relation to mortality, similar to the EU average
but marginally higher than the United Kingdom [19].
Annual decreases in age standardised mortality rates for
colorectal cancer in males and females were observed in
this study. However this concealed significant increases
in the mortality rate for rectal cancers of 2.4% in males
and 2.8% in females. Scrutiny of European data reveals
that most countries have experienced static mortality rates
over the past 15-20 years. However a few, in addition to
Ireland, have described increases. These include Spain,
with an APC of 3.5% during 1994-2005, Malta with an
APC of 5.2% during 1994-2008 and among selected regis-
tries in Germany with an APC of 17.1% during 1998-2007
[26]. In terms of potential explanations for these trends,
the first that must be considered is whether it might be an
artefact of coding of rectal cancer deaths. We have shown
that there was a significant decline in the annual death
rate for pooled colorectal sites. Yet, there was a steeper
decline in the rate of colon deaths, with a compensatory
increase in the rate for ‘rectum’ deaths. This suggests that
there may have been a subtle shift in death certificate cod-
ing allocation from ‘colon’ to ‘rectum’ over the period we
have examined. It has long been recognised that physi-
cians tend to report non-specific cancer sites on death
certificates; thus, if physicians change how they record
cause of death on the death certificate over time, this
may induce an apparent change in mortality rates [27]. In
1981, Percy et al reported that misclassification led to over
reporting of colon cancer deaths and underreporting of
rectal cancer deaths [27]. More recently, in the US, Yin
et al reported inaccurate coding of underlying cause of
death, with the vast majority of misclassifications beingcolon cancers incorrectly classified as rectal cancers [28].
Further investigation is warranted to explore the extent
and nature of misclassification on death certificates in
European countries in recent years, perhaps comparing
countries with rising and static rectal cancer mortality
rates.
Another possible explanation of the observed increase
in rectal cancer mortality is patterns in treatment utilisa-
tion. Pre-operative radiotherapy has been recommended
for resectable rectal cancer in recent years [29,30] and in
line with this the proportion who received pre-operative
radiotherapy has increased markedly since 2000, in Ireland
and in other countries [31]. However Carsin et al have
reported low use of radiotherapy in Ireland (27%) [31]
compared to US and EU populations (46%-62%) [32-34].
Moreover, although data from trials suggests that pre-
operative use is more effective, a significant proportion
treated with radiotherapy in Ireland receive it post-
operatively rather than pre-operatively [31]. These
observations raise the possibility that underuse of radio-
therapy, particularly preoperative radiotherapy, may be
a contributor to rectal cancer mortality trends. More-
over, while the current study found that radiotherapy
use was continuing to rise, any impact of this on mor-
tality rates will not be seen for several years.
In terms of surgery, evidence-based guidelines have
been published in Ireland aimed at standardising surgical
management of rectal cancer [30]. An audit of all rectal
cancers diagnosed in 2007 found that, while guidelines
were in place, best practice was frequently not adhered
to [35]. Surgery for rectal cancer can result in significant
morbidity if undertaken without appropriate and accur-
ate pre-operative staging. Accurate localisation of the
tumour [36-38], use of MRI (magnetic resonance im-
aging) [39] and ERUS (Endo-rectal ultrasound) [40-42]
as diagnostic tools, and recording of accurate pre-
operative histological data [43,44], are all essential for
successful treatment. However the national audit re-
vealed that there were often inadequate investigations
and/or recording of such data [35]. In addition while
multi-disciplinary meetings (MDM) have been shown
to improve outcomes for rectal cancer [45,46], treatment
options were only discussed at MDMs for around half of
patients. Moreover patients treated at low volume centres
were less likely to be discussed at MDMs and to have
neo-adjuvant therapy [35]. Further evidence suggests
that comorbidity, rather than age, in elderly rectal can-
cer patients increases risk of death after surgery [47].
Therefore age alone should not dictate the use of re-
storative rectal resection [47]. However, our analyses
indicate lower use of surgery in elderly than younger
patients (≥75; 81%; <75: 92-99%) as well as larger in-
creases in age standardised mortality in those aged 70
and older [13]. These observations, combined with
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http://www.biomedcentral.com/1471-230X/14/92likely under use of best practice, may provide a possible
explanation for the observed trends in mortality.
Biennial FIT-based screening in the 55-74 age group in
Ireland could reduce colorectal cancers deaths in the
population from as early as the second year of the
programme [10]. However, as noted earlier, screening is
being introduced in those aged 60-69, suggesting that it is
likely to take some considerable time to have any impact
on the trends in rectal cancer mortality reported here.
Conclusion
Age standardised incidence has remained static in
Ireland over the period 1994-2010, but 1-year and 5-year
survival continues to increase in both sexes. The propor-
tion of cases with late stage disease has increased over
time, as have mortality rates for rectal cancer. These
trends indicate the need for efficient and timely roll-out
of BowelScreen. However the narrow age-range at which
BowelScreen will operate in the first instance means that
the potential benefits of screening, in terms of more
advantageous stage distribution and reductions in colo-
rectal cancer incidence and mortality in the population,
are unlikely to be achieved in the short-term.
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